4//SEC Filing
Regulus Therapeutics Inc. 4
Accession 0001209191-15-035362
CIK 0001505512operating
Filed
Apr 20, 8:00 PM ET
Accepted
Apr 21, 7:06 PM ET
Size
21.5 KB
Accession
0001209191-15-035362
Insider Transaction Report
Form 4
XANTHOPOULOS KLEANTHIS G
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2015-04-17$16.94/sh−73,929$1,252,002→ 3,705 total - Exercise/Conversion
Common Stock
2015-04-20$0.38/sh+66,071$25,107→ 69,776 total - Sale
Common Stock
2015-04-20$16.85/sh−66,071$1,113,514→ 3,705 total - Exercise/Conversion
Common Stock
2015-04-21$0.38/sh+60,000$22,800→ 63,705 total - Exercise/Conversion
Common Stock
2015-04-17$0.38/sh+73,929$28,093→ 77,634 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-04-20−66,071→ 68,287 totalExercise: $0.38Exp: 2019-02-08→ Common Stock (66,071 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2015-04-17−73,929→ 134,358 totalExercise: $0.38Exp: 2019-02-08→ Common Stock (73,929 underlying) - Sale
Common Stock
2015-04-21$17.73/sh−60,000$1,063,980→ 3,705 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-04-21−60,000→ 8,287 totalExercise: $0.38Exp: 2019-02-08→ Common Stock (60,000 underlying)
Holdings
- 80,216(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]Includes an aggregate of 3,705 shares of Common Stock acquired by the Reporting Person pursuant to the Issuer's 2012 Employee Stock Purchase Plan, including 1,239 shares acquired on March 10, 2015.
- [F2]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted March 16, 2015.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.70 to $17.31 inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.45 to $17.41 inclusive. The reporting person undertakes to provide RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.43 to $18.30 inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- [F6]The shares subject to the option are fully vested.
Documents
Issuer
Regulus Therapeutics Inc.
CIK 0001505512
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001505512
Filing Metadata
- Form type
- 4
- Filed
- Apr 20, 8:00 PM ET
- Accepted
- Apr 21, 7:06 PM ET
- Size
- 21.5 KB